Poxel Stock

Poxel EBIT

The EBIT of Poxel (POXEL.PA) as of Aug 18, 2026 is -3.66 M EUR. In the previous year, EBIT was -29.38 M EUR — a change of -87.53% (higher).

EBIT

-3.66 MEUR

YoY

-87.53%

Last updated:

In 2026, Poxel's EBIT was -3.66 M EUR, a -87.53% increase from the -29.38 M EUR EBIT recorded in the previous year.

The Poxel EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M EUR)
Date
EBIT (M EUR)
Jan 1, 2019
-24.67 base
Jan 1, 2020
-30.54 base
Jan 1, 2021
-23.08 base
Jan 1, 2022
-27.09 base
Jan 1, 2023
-29.38 base
Jan 1, 2024
-3.66 base
Jan 1, 2025 (e)
-10.84 base
Jan 1, 2026 (e)
-26.55 base
YEAREBIT (M EUR)
2026 est -26.55
2025 est -10.84
2024 -3.66
2023 -29.38
2022 -27.09
2021 -23.08
2020 -30.54
2019 -24.67
2018 12.54
2017 -22.28
2016 -24.27
2015 -11.72
2014 -6.90
2013 -7.27
2012 -7.12
2011 -8.68
Access this data via the Eulerpool API

Poxel Revenue

Poxel Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
26.56 M EUR
-24.67 M EUR
-25.74 M EUR
Jan 1, 2020
6.81 M EUR
-30.54 M EUR
-31.86 M EUR
Jan 1, 2021
13.40 M EUR
-23.08 M EUR
-23.76 M EUR
Jan 1, 2022
674,000.00 EUR
-27.09 M EUR
-31.40 M EUR
Jan 1, 2023
1.98 M EUR
-29.38 M EUR
-35.09 M EUR
Jan 1, 2024
6.64 M EUR
-3.66 M EUR
-18.31 M EUR
Jan 1, 2025 (e)
11.60 M EUR
-10.84 M EUR
-66.66 M EUR
Jan 1, 2026 (e)
39.27 M EUR
-26.55 M EUR
-93.51 M EUR

Poxel Margins

Poxel stock margins

The Poxel margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Poxel. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Poxel.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
100.00 %
-92.90 %
-96.93 %
Jan 1, 2020
100.00 %
-448.71 %
-468.09 %
Jan 1, 2021
99.56 %
-172.28 %
-177.37 %
Jan 1, 2022
0.30 %
-4,018.84 %
-4,658.46 %
Jan 1, 2023
0.05 %
-1,482.94 %
-1,771.33 %
Jan 1, 2024
55.12 %
-55.18 %
-275.84 %
Jan 1, 2025 (e)
55.12 %
-93.41 %
-574.68 %
Jan 1, 2026 (e)
55.12 %
-67.60 %
-238.10 %

Poxel Stock analysis

What does Poxel do? Poxel SA is a biopharmaceutical company focused on developing drugs for the treatment of metabolic disorders, particularly type 2 diabetes. The company was founded in Lyon, France, in 2009. Poxel SA's business model is based on the targeted development of drugs for the treatment of metabolic disorders with high medical demand and large market potential. The company focuses on identifying drug candidates that are highly specific and effective while also having a favorable safety profile. Poxel SA collaborates closely with academic research and the industry to leverage the latest knowledge and technologies in drug development. Over the years, Poxel SA has become a leading company in metabolism medicine, with an extensive product pipeline of promising drug candidates. The product range includes both preclinical and clinical candidates, as well as products in advanced stages of clinical development. One of Poxel SA's main products is Imeglimin, a drug for the treatment of type 2 diabetes. Imeglimin is a new active ingredient that acts on the metabolic disorder in a novel way and improves the body's glucose metabolism. The drug is currently in the final phase of clinical development and has shown promising results in previous studies. Another promising product from Poxel SA is PXL770, a drug for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). PXL770 is a novel active ingredient that acts on the body's AMP-activated protein kinase system and regulates lipid and glucose metabolism. The drug is still in the clinical development phase but has already shown promising results. Another promising product group from Poxel SA are the adenosine monophosphate (AMP) activators, which are also being developed for the treatment of metabolic disorders such as type 2 diabetes and fatty liver disease. The AMP activators act on the body's AMP-activated protein kinase system and regulate lipid and glucose metabolism. Poxel SA also works closely with partners in the pharmaceutical industry to develop and bring innovative drug candidates to the market. The company has partnerships with leading companies such as Sumitomo Dainippon Pharma, Roivant Sciences, and Servier to expand and diversify its product pipeline. Overall, Poxel SA is an emerging company in metabolism medicine, focusing on the development of innovative drugs for the treatment of metabolic disorders. With a strong product pipeline and proven collaboration with academia and the industry, Poxel SA is a promising player in this growing market. Poxel is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Poxel's EBIT

Poxel's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Poxel's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Poxel's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Poxel’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Poxel stock

EBIT of Poxel is -3.66 M EUR in 2026.

EBIT of Poxel changed from -29.38 M EUR to -3.66 M EUR, representing a -87.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Poxel since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Poxel historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Poxel

All Key Metrics — Poxel